Surgery after immunotherapy to shrink lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at whether doing surgery after immunotherapy (with or without chemo) can be less invasive than originally planned. If your lung cancer shrunk enough after treatment that you might need a smaller surgery than first thought, this trial could help find the best approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC), a common type of lung cancer.
- You received immunotherapy (with or without chemo) before surgery, and it made the tumor smaller so surgery became possible.
- Originally, doctors planned to remove an entire lung or more than one lobe, but now they think a smaller surgery might work.
- You are 18 years or older and in good physical health (ECOG score 0 or 1).
- You have complete medical records, including scans and pathology reports.
- Your cancer did not get worse after the pre-surgery treatment, and you are healthy enough for surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
This trial tests whether combining chemo or targeted therapy before surgery can help people with non-small cell lung cancer that may require removing a whole lung. We want to see if this approach makes the surgery safer and more effective.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests whether giving immunotherapy before surgery helps people with lung cancer. It is for patients who have already started this treatment and are otherwise healthy.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.